1. A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
- Author
-
Arnulf Stenzl, Rudolf Morant, Manfred P. Wirth, Kurt Miller, and Ivan Zuna
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Metastatic Urothelial Carcinoma ,Cisplatin, Gefitinib, Gemcitabine, Transitional cell carcinoma, Urothelial carcinoma ,medicine.drug_class ,Urology ,medicine.medical_treatment ,Phases of clinical research ,Antineoplastic Agents ,Kaplan-Meier Estimate ,Deoxycytidine ,Drug Administration Schedule ,Tyrosine-kinase inhibitor ,Gefitinib ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,ddc:610 ,Epidermal growth factor receptor ,Neoplasm Metastasis ,Aged ,Aged, 80 and over ,Carcinoma, Transitional Cell ,Cisplatin, Gefitinib, Gemcitabin, Übergangszellkarzinom, Urothelkarzinom ,Chemotherapy ,biology ,business.industry ,Middle Aged ,medicine.disease ,Gemcitabine ,ErbB Receptors ,Treatment Outcome ,Transitional cell carcinoma ,Urinary Bladder Neoplasms ,Disease Progression ,Quinazolines ,biology.protein ,Female ,Cisplatin ,Urothelium ,business ,medicine.drug - Abstract
Introduction: This phase II trial evaluated the efficacy and safety of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, in combination with first-line chemotherapy in advanced urothelial cancer. Methods: Chemotherapy-naïve patients with advanced or metastatic urothelial carcinoma were randomized 1:1:1 to receive six cycles of chemotherapy (gemcitabine 1,250 mg/m2 on days 1 and 8, and cisplatin 70 mg/m2 on day 1 of every cycle) concomitantly with gefitinib 250 mg/day (arm A); or with sequential gefitinib (arm B); or alone (arm C). The primary endpoint was the time to progression (TTP). Results: A total of 105 patients received study treatment. Median TTP for arms A, B, and C were 6.1, 6.3, and 7.8 months, respectively. There were no significant differences between treatment arms for any outcomes measured. The most common adverse events were nausea and vomiting. Conclusion: Gefitinib in combination with chemotherapy did not improve efficacy in advanced urothelial cancer.
- Published
- 2015
- Full Text
- View/download PDF